"Retatrutide Clinical Development: Safety and Efficacy in Phase 2 Trials." Clinical Endocrinology and Metabolism Review, 2024
A landmark physiology paper published in Obesity Reviews modeled the mathematics precisely
doi: 10.3389/fendo.2025.1569468 Received 31 January 2025 Accepted 27 May 2025 Published 18 June 2025 Corrected 02 October 2025 Volume 16 - 2025 Edited by Chanan Meydan, Rabin Medical Center, Israel Reviewed by Michail Kokkorakis, Harvard Medical School, United States Danny Sugimoto, Cedar Crosse Research Center, United States Updates Copyright 2025 Steenackers, Toumassian, Deleus, Mertens, Lannoo, Pazmino, van Laar, Van der Schueren and Vangoitsenhoven
We now know that patients frequently discontinue GLP-1 therapy within months, negating long-term benefits, and also struggle to meet the requirements of lifestyle changes that are prescribed alongside the medication
No matter how much I work out or have a diet plan I seem to be fluctuating within 144-145 I hope this helps